Hydroxyethyl starch and acute kidney injury in high-risk patients undergoing cardiac surgery: A prospective multicenter study

Hydroxyethyl starch (HES) solutions increase the risk of acute kidney injury (AKI) in critically ill patients admitted to intensive care unit (ICU) for medical indications. We conducted a cohort study to evaluate the renal safety of modern 6% HES solutions in high-risk patients having cardiac surger...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical anesthesia 2021-10, Vol.73, p.110367-110367, Article 110367
Hauptverfasser: Nagore, David, Candela, Angel, Bürge, Martina, Monedero, Pablo, Tamayo, Eduardo, Alvarez, J., Murie, Manuel, Wijeysundera DN, Duminda N., Vives, Marc, Mendez, Esther, Pasqualetto, Alberto, Mon, Tomas, Pita, Rafael, Varela, Maria Angela, Esteva, Carlos, Pereira, Miguel Angel, Sanchez, Juan, Rodriguez, Maria Angeles, Garcia, Alvaro, Carmona, Paula, López, Marta, Pajares, Azucena, Vicente, Rosario, Aparicio, Rosa, Gragera, Isabel, Calderon, Enrique, Marcos, Jose Miguel, Gómez, Laura, Rodriguez, Jose Maria, Matilla, Adolfo, Medina, Ana, Morales, Laura, Santana, Luis, Garcia, Estefania, Montesinos, Santiago, Muñoz, Pedro, Bravo, Blanca, Alvarez, Julian, Blanco, Verónica
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hydroxyethyl starch (HES) solutions increase the risk of acute kidney injury (AKI) in critically ill patients admitted to intensive care unit (ICU) for medical indications. We conducted a cohort study to evaluate the renal safety of modern 6% HES solutions in high-risk patients having cardiac surgery. In this multicentre prospective cohort study, we recruited 261 consecutive patients at high-risk for developing cardiac surgery-associated AKI, based on a Cleveland score ≥ 4 points, from July to December 2017th in 14 hospitals in Spain and the United Kingdom. Multivariable logistic regression modeling and propensity-score matched-pairs analysis were used to determine the adjusted association between administration of HES and AKI. Of the cohort, 95 patients (36.4%) received 6% HES 130/0.4 either intraoperatively or postoperatively. Postoperative AKI occurred in 145 patients (55.5%). The unadjusted odds of AKI was significantly higher in the HES group, when compared to those not receiving HES (OR 2.22, 95% CI 1.30–3.80, p = 0.003). In multivariable logistic regression models, modern HES was not associated with significantly increased risk of AKI (adjusted OR 0.84, 95% CI 0.41–1.71, p = 0.63). In propensity score match-pairs analysis of 188 patients, the HES group experienced similar adjusted odds of AKI (OR 1.05, CI 95% 0.87–1.27, p = 0.57) and RRT (OR 1.06, CI 95% 0.92–1.22, p = 0.36). The use of modern hydroxyethyl starch 6% HES 130/0.4 was not associated with an increased risk of AKI nor dialysis in this cohort of patients at elevated risk for developing AKI after cardiac surgery. •This is a multicenter prospective cohort study, with high-risk patients for developing CSA-AKI.•Modern Hydroxyethyl starch was not associated with an increased risk of AKI in high-risk patients for developing CSA-AKI.•Multivariable logistic regression modeling and propensity-score matched-pairs analysis were used.
ISSN:0952-8180
1873-4529
DOI:10.1016/j.jclinane.2021.110367